{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:34:20Z","timestamp":1791470060644,"version":"4.3.4"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamaoncol.2019.0836","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:31:54Z","timestamp":1559230314000},"page":"999","source":"Crossref","is-referenced-by-count":71,"title":["Assessment of Subcutaneous vs Intravenous Administration of Anti\u2013PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors"],"prefix":"10.1001","volume":"5","author":[{"given":"Melissa L.","family":"Johnson","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Braiteh","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center of Nevada, University of Nevada, Las Vegas School of Medicine, Las Vegas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juneko E.","family":"Grilley-Olson","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chou","sequence":"additional","affiliation":[{"name":"Pfizer Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Davda","sequence":"additional","affiliation":[{"name":"Pfizer Inc, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Forgie","sequence":"additional","affiliation":[{"name":"Pfizer Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Kazazi","sequence":"additional","affiliation":[{"name":"Pfizer Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi190024r1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy.","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"8","key":"coi190024r2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"issue":"6382","key":"coi190024r3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"coi190024r4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily.","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"coi190024r5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity.","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"coi190024r6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy.","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"13","key":"coi190024r12","article-title":"In vitro properties and pre-clinical activity of PF-06801591, a high-affinity engineered anti-human PD-1","volume":"77","author":"Youssef","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"coi190024r13","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"coi190024r14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi190024r15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","article-title":"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.","volume":"102","author":"Lugtenburg","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"coi190024r16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"coi190024r17","doi-asserted-by":"publisher","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.","volume":"10","author":"Minarik","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"coi190024r18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"coi190024r19","doi-asserted-by":"crossref","first-page":"927105","DOI":"10.1155\/2015\/927105","article-title":"Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients.","volume":"2015","author":"Wu","year":"2015","journal-title":"Biomed Res Int"},{"issue":"8","key":"coi190024r20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.","volume":"29","author":"Franken","year":"2018","journal-title":"Anticancer Drugs"},{"issue":"12","key":"coi190024r21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"coi190024r22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","article-title":"Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer\u2014an observational study prospectively recording resource utilization in a Swedish healthcare setting.","volume":"29","author":"Olofsson","year":"2016","journal-title":"Breast"},{"issue":"10","key":"coi190024r23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi190024r24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"coi190024r25","first-page":"227","article-title":"Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin\u2019s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey.","volume":"8","author":"Ponzetti","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"coi190024r26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"coi190024r27","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi190024r28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","article-title":"A modified toxicity probability interval method for dose-finding trials.","volume":"7","author":"Ji","year":"2010","journal-title":"Clin Trials"},{"issue":"19","key":"coi190024r29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, In patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study.","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi190024r30","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190024r31","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"coi190024r32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"34","key":"coi190024r33","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi190024r34","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"coi190024r35","first-page":"423","article-title":"Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.","volume":"7","author":"North","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"coi190024r36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10637-016-0411-2","article-title":"Phase I study of nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.","volume":"35","author":"Yamamoto","year":"2017","journal-title":"Invest New Drugs"},{"issue":"7","key":"coi190024r37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"coi190024r38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/psp4.12133","article-title":"Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma.","volume":"6","author":"Wang","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"coi190024r39","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins.","volume":"106","author":"Hamuro","year":"2017","journal-title":"J Pharm Sci"},{"key":"coi190024r40","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy288.013","article-title":"Phase I study of KN035: a novel fusion anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA.","volume":"29","author":"Papadopoulos","year":"2018","journal-title":"Ann Oncol"},{"issue":"10064","key":"coi190024r41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"10031","key":"coi190024r42","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"coi190024r43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"coi190024r7","unstructured":"Imfinzi (durvalumab) injection for intravenous use [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2017. https:\/\/www.azpicentral.com\/imfinzi\/imfinzi.pdf#page=1. Accessed September 10, 2018."},{"key":"coi190024r8","unstructured":"OPDivo (nivolumab) solution, intravenous infusion [package insert]. Princeton, NJ: Bristol-Myers Squibb Co. 2017. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed September 10, 2018."},{"key":"coi190024r9","unstructured":"Bavencio (avelumab) for intravenous use [package insert]. Rockland, MD: Serono EMD. 2017. http:\/\/www.emdserono.com\/bavencioPrescribingInformation. Accessed September 10, 2018."},{"key":"coi190024r10","unstructured":"Tecentriq (atezolizumab) for intravenous infusion [package insert]. San Francisco, CA: Genentech. 2017. https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed September 10, 2018."},{"key":"coi190024r11","unstructured":"Keytruda (pembrolizumab) lyophilized powder; intravenous infusion [package insert]. County Cork, Ireland: Merck & Co. 2017. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed September 10, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/7\/999\/17712497\/jamaoncology_johnson_2019_oi_190024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T22:09:49Z","timestamp":1663538989000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2019.0836"}},"subtitle":["A Phase 1 Dose-Escalation Trial"],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.0836","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}